Skip to content New The AI buying guide for BD&L executives — now available on demand Watch
Resources

Latest thinking

Scientific insights, BD frameworks, and the reasoning behind assessments — written for the people who have to defend the decision.
Featured · Scientific insight

Scientific insights: Why China Now Owns the Late-Stage IL-4R Pipeline

Chinese companies now run seven of the eight IL-4Rα assets in Phase III — and the eighth is licensed to China too, with MG-K10’s latest Phase III data (94.3% EASI-75 at week 52) showing exactly why this comp set can’t be ignored. The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target.

Scientific insights
Scientific insight

Scientific insights: Why China Now Owns the Late-Stage IL-4R Pipeline

Chinese companies now run seven of the eight IL-4Rα assets in Phase III — and the eighth is licensed to China too, with MG-K10’s latest Phase III data (94.3% EASI-75 at week 52) showing exactly why this comp set can’t be ignored. The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target. Scientific insight
Scientific insight

Scientific insights: TLR7 in lupus- Daiichi Sankyo’s DS-7011a

Daiichi Sankyo’s anti-TLR7 antibody just completed Phase 1b/2 — here’s how VibeOne sees the TLR7/8 landscape in lupus today. The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target. Scientific insight
Scientific insight

Scientific insights: The Integrin α4β7 landscape in IBD

Eli Lilly’s $3.2B acquisition of Morphic put renewed focus on Integrin α4β7 as a target in IBD. In collaboration with Sleuth, we assessed the competitive landscape and key risks for MORF-057—including its differentiation potential as a gut-selective oral therapy. Scientific insight
Blog

Strategy & Due Diligence in Pharma Business Development

Pharma growth depends on smarter BD decisions. This article outlines a clear framework to evaluate external opportunities before committing to formal diligence. Blog
Scientific insight

Scientific insights: CKD

VibeOne analyzed 100+ CKD programs and found a clear pattern: small molecules dominate and repurposed drugs win. The next kidney breakthrough may already be in a cardiovascular trial. Scientific insight
Scientific insight

Scientific insights:The ActRIIB Challenge (LAE103)

The obesity market is undergoing a quiet revolution: it’s no longer about how much weight patients lose, but what kind of weight they lose. Scientific insight
Scientific insight

Scientific insights: Urea cycle disorders

Drug hunters need to watch Urea Cycle Disorders! Gene therapies (cost) and ERTs (patient experience) still leave much to be desired. Scientific insight
Scientific insight

Scientific insights: Kidney disease

Explore why kidney disease is emerging as a top therapeutic focus. See how VibeOne identifies high-potential kidney indications and guides strategic prioritization. Scientific insight
Whitepaper

Whitepaper: The AI buying guide for BD&L executives

AI is already transforming how leading organizations identify, evaluate, and close deals, but not all AI platforms are built for BD&L. Whitepaper
Scientific insight

Scientific insights: Fabry disease

Fabry disease may seem niche, but it’s becoming a bellwether for how global innovation and modality shifts are reshaping rare disease pipelines. Scientific insight
Blog

Why BD teams cannot afford to lose their memory & how AI can help

Even with databases, access to prior knowledge in biotech BD teams often breaks down. The antidote is simple : build durable organizational memory. AI can help. Blog
Case study

Increasing hope in rare disease — how Incite partnered with Vibe Bio to accelerate the search & evaluation of sarcoma drugs

Learn how Incite partnered with Vibe Bio to accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis. Case study
Case study

How Orphan Therapeutics Accelerator is optimizing rare disease search & eval

Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy. Case study
Blog

From overwhelm to clarity: prioritizing assets with AI-powered confidence

Facing a flood of biopharma assets? Learn how AI can help your BD team cut through the noise, gain confidence, and act with purpose. Blog
Blog

Modern biopharma BD: How to find the diamonds in the rough

Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking. Blog
Blog

Navigating pharma strategy and portfolio prioritization: A Q&A

With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization. Blog
Blog

Lessons from a pioneer in pharmaceutical decision-making

Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and probability assessment approaches. Blog
News

Orphan Therapeutics Accelerator Announces Foundational Partnerships

The Orphan Therapeutics Accelerator, a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions News
Blog

Biopharma BD&L: the tsunami is upon us

Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future. Blog
Blog

Improving biopharma BD with AI-powered due diligence

In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints. Blog
Blog

Pharma portfolio analytics in a gen AI world

I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in. Blog
Blog

Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD

Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks. Blog
Blog

The Great Disruption: how Chinese assets will reshape drug development

Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development. Blog
Blog

5 insights from JPM 2025

Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface. Blog

Get the latest thinking as it publishes

"*" indicates required fields

This field is for validation purposes and should be left unchanged.